Receive our newsletter – data, insights and analysis delivered to you
  1. Special Focus
  2. Covid-19
April 17, 2020

University of Waterloo to develop nasal vaccine for Covid-19

By Duncan West

University of Waterloo researchers in Canada are developing a DNA-based vaccine candidate that can be given via nasal route to protect from Covid-19 infection.

The vaccine will use bacteriophage-based approach, which will allow it to replicate within bacteria already present in the body, formulated to act on tissues in the nasal cavity and lower respiratory tract.

The aim is to deliver the vaccine to cells in targeted tissues and trigger the production of a virus-like particle (VLP) that will induce an immune response.

Read the full article here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU